Healthcare AI & Digital Health — 2026年9月1日 月次レポート
Healthcare AI & Digital Healthのニュース＆アップデート — すべての記述に一次ソースのリンク付き。
重要な発見
エグゼクティブサマリー（5件）
- •The FDA's approval pipeline delivered an unusually dense cohort of first-in-class therapies and devices across oncology, rare disease, neurology, and diagnostics in a single month — a throughput level that will compress competitive response timelines for incumbents across multiple therapeutic categories simultaneously.
- •Healthcare AI governance crossed a structural threshold: the MHRA's operational sandbox, the FDA's generative AI public comment process, Japan's AX/DX Promotion Headquarters, and the AMA's physician AI ethics CME series collectively signal that self-regulation in healthcare AI has ended and formal multi-jurisdictional compliance requirements are now being built.
- •Medtech cybersecurity became a systemic sector risk rather than an isolated compliance issue, with Boston Scientific, Stryker, and a major revenue cycle vendor all breached within weeks — demonstrating that cyberattacks now carry direct patient access and supply chain consequences, not just data privacy exposure.
- •The UK MHRA's combination of first-mover approvals (oral GLP-1, simultaneous MHRA-NICE model), new regulatory frameworks (microbiome, digital mental health, ambient voice), and operational AI sandbox positions the UK as the most commercially accessible major regulatory market for novel therapeutic and digital health developers.
- •Converging cost pressures — 9–9.5% projected employer cost increases, FTC antitrust scrutiny of Epic, and state-level enforcement of spending targets — are shifting healthcare cost containment from aspiration to coercive policy, creating structural demand for value-based care models and AI-driven administrative efficiency at scale.
今回の要点（7件）
- 1.The FDA sustained an extraordinary first-in-class approval cadence across the entire month: freeze-dried plasma (July 29), first full-symptom narcolepsy type 1 drug (Aug 5), Replimune's Tudriqev for treatment-resistant melanoma (Aug 6), BMS's Zenbexus as the first CELMoD for multiple myeloma, Ultragenyx's Genglycos as the first gene therapy for Glycogen Storage Disease Type Ia (Aug 19), and a cluster of four first-in-class approvals in the final week alone — including Revolution Medicines' darax…
- 2.Healthcare AI governance moved from policy to operational infrastructure across three jurisdictions: the MHRA launched its AI health innovations regulatory sandbox (July 30) and published ambient voice technology guidance; the FDA opened formal public comment on generative AI medical device regulation (Aug 18) and scheduled digital health endpoint workshops; Japan's MHLW established the Healthcare AX/DX Promotion Headquarters (Aug 3) and PMDA launched the ENSEMBLExJ One-Stop Service Platform (Au…
- 3.Medtech cybersecurity escalated from isolated incidents to a systemic sector crisis: Boston Scientific disclosed a cyberattack disrupting global IT systems and order shipping (Aug 26), Stryker disclosed a network disruption (Aug 28), a phishing campaign impersonating Epic's MyChart targeted over a dozen health systems, and a ransomware attack on revenue cycle vendor Unlimited Technology Systems exposed 3.8 million patient records — the second-largest healthcare data breach reported to HHS this y…
- 4.The UK MHRA established itself as the most structurally active regulatory environment for novel therapeutics: first in Europe to authorize oral GLP-1 orforglipron (Aug 10), simultaneous MHRA-NICE approval model demonstrated for aficamten (July 30), Innovation Passports granted for liver cancer and dementia products, and new regulatory frameworks published for microbiome-based medicines and digital mental health technology [10].
- 5.The Cyclospora outbreak linked to Taylor Farms de Mexico iceberg lettuce grew from an initial multi-state event to 10,930 illnesses, 454 hospitalizations, and 2 deaths by Aug 20 — despite a recall in place since July 17 — with FDA expanding inspections to iceberg lettuce growers across Mexico, exposing systemic produce supply chain traceability failures [14].
- 6.Digital health M&A and investment accelerated: Function Health raised $450 million from General Catalyst eight months after its $298 million Series B; Salesforce secured a $1.6 billion VA agentic AI contract; Sword Health agreed to acquire Headspace; and Cityblock acquired Homeward Health with a $116 million Series E — reflecting consolidation around integrated, employer-facing platforms [6].
- 7.Employer healthcare cost projections for 2027 converged around 9–9.5% increases (Aon: 9.5%, Business Group on Health: 9.2%), while the FTC opened an antitrust investigation into Epic's data-sharing practices and the AMA launched its Ethical AI Use in Medicine CME Series — signaling that cost pressure, platform scrutiny, and AI governance are simultaneously intensifying [5].
市場動向
FDA First-in-Class Approval Cadence Broadens Across Therapeutic Categories Month-Over-Month
Building on June 2026's advanced therapy guidances and OTC CGM clearance, August 2026 saw the FDA sustain an elevated approval throughput across oncology (RAS inhibitor for pancreatic cancer, CELMoD for multiple myeloma, oncolytic viral therapy for melanoma), rare disease (gene therapy for Glycogen Storage Disease Type Ia), neurology (first full-symptom narcolepsy type 1 drug), hematology (first drug for polycythemia vera), autoimmune (first oral drug for dermatomyositis), and diagnostics (first…
Healthcare AI Deployment Outpaces Governance Infrastructure, Driving Sector-Wide Oversight Response
A pattern established in June 2026 — where real-world AI failures triggered institutional responses — intensified through August. The FDA opened public comment on generative AI medical device regulation (Aug 18) [2], the AMA launched physician AI ethics CME (Aug 26), and MedCity News reported hospitals are broadly adopting AI but oversight has not kept pace. Epic's FTC antitrust investigation (Aug 17) and the AI governance gap study reported by Fierce Healthcare collectively confirm that deploym…
Medtech Cybersecurity Escalates From Isolated Incidents to Systemic Sector Risk
The month's cybersecurity events represent a qualitative shift from the prior period's data breach pattern. Boston Scientific's cyberattack disrupted global order shipping — not just data systems — with no restoration timeline [24]. Stryker disclosed a concurrent network disruption. A ransomware attack on revenue cycle vendor Unlimited Technology Systems exposed 3.8 million patient records [6]. A phishing campaign impersonating Epic's MyChart targeted over a dozen health systems simultaneously. …
Employer and State Cost Containment Pressure Shifts From Aspiration to Enforcement
Employer healthcare cost projections for 2027 converged at 9–9.5% (Aon: 9.5% [5]; Business Group on Health: 9.2% [6]), while California joined at least eight states setting provider spending growth targets with enforcement penalties. KFF reported insurers denied 12–18% of standard prior authorization requests in 2025. These parallel pressures — from employers, state governments, and payers — indicate cost containment is becoming coercive, creating structural demand for AI-driven administrative e…
Digital Health M&A Consolidates Around Integrated, Employer-Facing Platforms
The month's deal activity reflected a consistent consolidation logic: Included Health acquiring Firefly Health for employer alternative health plans, Doctronic acquiring Summer Health for pediatric primary care, Sword Health acquiring Headspace to combine musculoskeletal and mental health, and Cityblock acquiring Homeward Health with a $116 million Series E [6]. Function Health's $450 million raise from General Catalyst [6] and Salesforce's $1.6 billion VA agentic AI contract [5] further illustr…
競合動向
Epic Deepens Platform Moat While Facing FTC Antitrust Scrutiny
Epic's competitive expansion accelerated through August: diagnostic image exchange (Aug 13), AI nursing documentation at Mount Sinai, real-time prior authorization checks at four health systems (Aug 17), Ergo Visit AI outpatient tool at Ochsner Health (Aug 18), and Agent Factory showcased at its annual conference [13]. Simultaneously, the FTC opened an antitrust investigation into Epic's data-sharing practices (Aug 17) [5]. The same integration that creates clinical value is now drawing regulato…
MHRA Establishes First-Mover Regulatory Frameworks Across Multiple Emerging Categories
The MHRA's August output extended its June 2026 AI sandbox and oral semaglutide approval pattern into new categories: first in Europe to authorize oral GLP-1 orforglipron (Aug 10), new regulatory framework for microbiome-based medicinal products (Aug 18), updated digital mental health technology guidance (Aug 19), and ambient voice technology guidance developed with NHS England (July 29) [10]. This systematic use of post-Brexit regulatory independence to create first-mover frameworks positions t…
Siemens Healthineers and Philips Compete for ARPA-H AI Robotics Positioning
Siemens Healthineers secured ARPA-H funding of up to $31.1 million over five years for autonomous remote endovascular robotics for acute stroke treatment [11], while Philips was selected for a separate ARPA-H program to advance AI-enabled robotic stroke care (Aug 26) [18]. Both companies are now in a government-validated AI robotics cohort for acute neurological care — a competitive positioning that de-risks early-stage investment and could accelerate regulatory and commercial pathways for remot…
Japan Builds Coordinated Digital Health Regulatory Infrastructure Across MHLW and PMDA
Japan's MHLW established the Healthcare AX/DX Promotion Headquarters (Aug 3) [16], PMDA launched the updated ENSEMBLExJ One-Stop Service Platform (Aug 18), and the 6th SaMD Industry-Academia-Government Collaboration Forum was announced (Aug 20). PMDA continued publishing English-language review reports for novel devices including Optune Lua and the Esprit BTK scaffold. This coordinated institutional build — extending PMDA's June 2026 AI Guiding Principles project team — signals Japan is systemat…
Pharma Autoimmune and Oncology M&A Race Intensifies With New Entrants
J&J paid $785 million to partner with Sail Biosciences on cell therapy for autoimmune diseases with a $2.58 billion acquisition option [6], Jazz Pharmaceuticals acquired Actio Biosciences for $820 million in its second epilepsy deal in one year, and Deerfield Management formed Boulevard Bio with autoimmune kidney disorder focus. AstraZeneca-Amgen's Tezspire met Phase 3 goals in eosinophilic esophagitis, positioning it as the first credible biologic competitor to Sanofi's Dupixent in that indicat…
制度・規制動向
FDA Transitions From Ad Hoc AI Device Review to Structured Generative AI Framework
The FDA's July 2026 TEMPO digital health pilot selection was followed by a formal public comment process on generative AI medical device regulation (Aug 18) [2] and scheduled workshops on digitally-derived endpoints (Aug 27) and quantitative medicine (Sep 1). This progression — from pilot program to public comment to workshop series — represents a deliberate framework-building sequence with broad implications for every digital health company deploying large language models or generative AI in cl…
MHRA-NICE Coordinated Approval Model Emerges as Replicable UK Market Access Pathway
The simultaneous MHRA approval and NICE recommendation for aficamten (July 30), with approximately 6,600 patients in England expected to benefit immediately [12], was followed by a second instance of coordinated action for a heart condition treatment in August. NICE also conditionally recommended a lung preservation machine under a managed access framework. This pattern — simultaneous regulatory approval and health technology assessment — is becoming a structural feature of UK market access rath…
MDUFA VI and FDA Commissioner Nomination Create Pivotal Medtech Regulatory Policy Window
AdvaMed expressed strong support for the draft MDUFA VI agreement at an FDA public hearing (Aug 5) [17], with a final commitment letter to Congress due by January 15, 2027 and legislation required by September 30, 2027. President Trump nominated Dr. Heidi Overton as FDA Commissioner (Aug 19) [25]. The convergence of new leadership and active user fee negotiations creates a defined window for medtech industry stakeholders to shape review timeline commitments and AI-enabled device treatment in the…
Coordinated Multi-Body Vaccination Safety Counter-Narrative Responds to Political Pressure
The AMA warned against altering the childhood vaccination schedule without credible evidence (Aug 10) [20], the MHRA reaffirmed childhood vaccination safety (Aug 12), and Cochrane led a consortium of global public health organizations in a collective vaccination safety statement (Aug 21) [19]. CDC data showed kindergarten vaccination rates declined only 0.1%. This organized scientific counter-narrative — spanning professional bodies, regulators, and evidence synthesis organizations — signals tha…
ソース活動
先月からの変化
MHRA Launches AI Health Innovations Regulatory Sandbox
The MHRA launched its AI health innovations regulatory sandbox on July 30, 2026 [10], operationalizing the AI sandboxes announced in June 2026. This is the first operational pre-market regulatory engagement mechanism specifically for AI health products in the UK, representing a structural advance beyond the prior month's policy paper commitments.
FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S.
On July 29, 2026, the FDA licensed the first-ever freeze-dried plasma product in the United States [2], extending the FDA's landmark approval cadence into emergency medicine and blood products.
Function Health Raises $450M From General Catalyst for Preventive Care Expansion
Function Health raised $450 million from General Catalyst's Customer Value Fund just eight months after its $298 million Series B, to expand lab testing and imaging services [6]. One of the largest single digital health raises of the period, signaling strong institutional conviction in preventive care platforms.
Salesforce Lands $1.6B VA Deal for Agentic AI in Healthcare
Salesforce secured a $1.6 billion deal with the VA to advance agentic AI [5], marking one of the largest single government AI healthcare contracts and signaling that autonomous AI agents are entering large-scale federal healthcare deployment.
MHRA-NICE Simultaneous Approval-Recommendation Model Demonstrated for Aficamten
On July 30, 2026, MHRA approved aficamten at the same time NICE recommended it, with approximately 6,600 patients in England expected to benefit immediately [12]. This coordinated model, driven by closer working between the two organizations, was replicated in August for a second heart condition treatment, establishing it as a replicable UK market access pathway.
FDA Approves Replimune's Tudriqev for Treatment-Resistant Melanoma
On August 6, 2026, the FDA approved Replimune's Tudriqev — an engineered viral immunotherapy — for treatment-resistant advanced melanoma, going from FDA rejection to accelerated approval in less than four months [6]. First-in-class approval in the oncolytic viral therapy space for this indication.
FDA Approves First Full-Symptom Narcolepsy Type 1 Drug
On August 5, 2026, the FDA approved the first drug to treat the full range of narcolepsy type 1 symptoms, including targeting the condition's underlying cause [2]. First-in-class approval extending the FDA's landmark cadence into neurology and sleep medicine.
Japan MHLW Establishes Healthcare AX/DX Promotion Headquarters
Japan's MHLW announced the first Healthcare AX/DX Promotion Headquarters on August 3, 2026 [16], formalizing government-level coordination for healthcare digital transformation. This builds on PMDA's June 2026 AI Guiding Principles project team and complements PMDA's ENSEMBLExJ One-Stop Service Platform launched August 18.
MDUFA VI Draft Agreement Advances Toward Congressional Enactment
AdvaMed expressed strong support for the draft MDUFA VI agreement at an FDA public hearing on August 5, 2026 [17]. FDA will send a final commitment letter to Congress by January 15, 2027, with legislation required by September 30, 2027. Directly affects medical device review timelines and user fee structures for the next authorization cycle.
Cyclospora Outbreak Grows to 10,930 Cases With FDA Expanding Mexico Inspections
The multistate Cyclospora outbreak linked to Taylor Farms de Mexico iceberg lettuce escalated from initial multi-state reports to 10,930 illnesses, 454 hospitalizations, and 2 deaths as of August 20, 2026 [14], despite a recall in place since July 17. FDA expanded inspections to iceberg lettuce growers across Mexico, suggesting contamination broader than a single supplier.
MHRA First in Europe to Authorize Oral GLP-1 Orforglipron
On August 10, 2026, the MHRA became the first regulator in Europe to authorize orforglipron, an oral GLP-1 receptor agonist, for weight management and type 2 diabetes [10], extending the UK's first-mover GLP-1 pattern established with oral semaglutide in June 2026.
BMS Zenbexus Wins First-in-Class FDA Approval as First CELMoD for Multiple Myeloma
Bristol Myers Squibb's Zenbexus received FDA approval as the first drug in the new CELMoD class for multiple myeloma, as reported by MedCity News on August 15, 2026 [6]. BMS is positioning this as a successor to its legacy multiple myeloma products.
Ransomware Attack on Revenue Cycle Vendor Exposes 3.8 Million Patient Records
Revenue cycle vendor Unlimited Technology Systems disclosed a ransomware attack affecting 3.8 million patients — the second-largest healthcare data breach reported to HHS this year [6]. Illustrates an evolving threat pattern targeting third-party administrative infrastructure at the intersection of clinical and financial data.
FDA Seeks Public Input on Generative AI Medical Device Regulatory Framework
On August 18, 2026, the FDA announced it is seeking public feedback to inform its regulatory approach for generative AI-enabled medical devices [2]. The FDA's first formal public engagement process specifically targeting generative AI in medical devices, signaling a shift from case-by-case review toward a structured framework.
FDA Authorizes First Robotic Blood Draw Device and Approves Gene Therapy for Glycogen Storage Disease
On August 19, 2026, the FDA authorized the first-of-its-kind robotic blood draw device and approved Ultragenyx's Genglycos — the first therapy for Glycogen Storage Disease Type Ia and Ultragenyx's first approved gene therapy [1] [6].
Epic Faces FTC Antitrust Investigation While Launching New AI Tools
The FTC opened an antitrust investigation into Epic's data-sharing practices on August 17, 2026 [5], while Epic simultaneously launched real-time prior authorization checks at four health systems and the Ergo Visit AI outpatient tool at Ochsner Health [13].
Dr. Heidi Overton Nominated as FDA Commissioner
President Trump nominated Dr. Heidi Overton as FDA Commissioner on August 19, 2026, with AdvaMed welcoming the nomination and emphasizing the importance of transparency and predictability at CDRH [25]. The nomination coincides with active MDUFA VI negotiations.
FDA Issues Multiple First-in-Class Approvals in Final Week of August
The FDA approved Revolution Medicines' daraxonrasib (Rasonque) as the first RAS inhibitor for pancreatic adenocarcinoma (Aug 26), authorized the first wearable monitoring both ketone levels and blood sugar (Aug 25), approved Roivant's Lisraya as the first oral drug for dermatomyositis (Aug 27), and approved the first drug of its kind for polycythemia vera (Aug 28) [1] [6].
Boston Scientific Cyberattack Disrupts Global Operations; Stryker Also Discloses Network Disruption
Boston Scientific disclosed a cyberattack disrupting global IT systems and order shipping with no restoration timeline (Aug 26) [24]. Stryker disclosed a concurrent network disruption (Aug 28) [21]. MedCity News reported this adds both companies to a 2026 pattern of major medtech cyberattacks including Medtronic and Abbott [6].
AMA Launches Ethical AI Use in Medicine CME Series
The AMA introduced its Ethical AI Use in Medicine Series on August 26, 2026, providing case-based CME to equip physicians to evaluate, implement, and oversee AI using guidance grounded in medical ethics [20]. The first formal physician education initiative from the AMA specifically targeting AI governance at the point of care.
Sword Health Acquires Headspace in Digital Health Mental Health Consolidation
Fierce Healthcare reported on August 26, 2026 that Sword Health agreed to acquire Headspace in an all-cash deal targeting a September close, combining virtual physical therapy and mental health platforms [5]. Reflects consolidation logic mirroring integrated behavioral-physical health benefit designs demanded by large employers and payers.
Merck-Moderna mRNA Cancer Vaccine Meets Pivotal Trial Goals in Melanoma
MedCity News reported on August 20, 2026 that Merck and Moderna's personalized mRNA cancer vaccine intismeran autogene met the main goal of a pivotal test in melanoma — the most advanced trial in their 50/50 partnership evaluating the treatment across a wide range of tumor types [6].
Philips Selected for ARPA-H AI Robotic Stroke Care Program
Philips was selected for an ARPA-H program to advance AI-enabled robotic stroke care on August 26, 2026 [18], directly entering the government-backed AI robotics space where Siemens Healthineers received ARPA-H funding the prior week. Creates a two-company ARPA-H AI robotics cohort for acute neurological care.
MHRA Publishes Regulatory Frameworks for Microbiome Medicines and Digital Mental Health
The MHRA published a position paper clarifying the UK licensing route for microbiome-based medicinal products (Aug 18) and updated guidance on digital mental health technology (Aug 19) [10], extending its pattern of creating first-mover regulatory clarity for emerging therapeutic and digital health categories.
Cochrane-Led Consortium Issues Coordinated Childhood Vaccination Safety Statement
Cochrane and a consortium of global public health organizations issued a collective statement on August 21, 2026 reaffirming the safety and effectiveness of childhood vaccination including the MMR vaccine [19], following AMA and MHRA statements and CDC data showing only a 0.1% decline in kindergarten vaccination rates.
示唆・見るべき論点（10件）
- 1.The FDA's generative AI medical device public comment process (Aug 18) [2] is the single highest-leverage regulatory engagement opportunity of the month for digital health AI companies: organizations that submit substantive comments will have an informational and potentially structural advantage in shaping the framework that will govern their products. The window to influence this framework is now open and time-limited.
- 2.The FTC antitrust investigation into Epic's data-sharing practices [5] could, if it results in interoperability mandates, create the largest structural opening for Epic competitors in a decade. Health IT vendors and digital health companies should monitor this investigation as a potential catalyst for market restructuring and begin positioning their interoperability capabilities accordingly.
- 3.The clustering of cyberattacks across Boston Scientific, Stryker, Unlimited Technology Systems, and the MyChart phishing campaign within a single month signals that healthcare's digital infrastructure has crossed a threshold where cybersecurity is a patient safety and supply chain continuity issue — not just a compliance matter. Health systems and medtech companies should treat supply chain continuity as a cybersecurity outcome metric and extend due diligence comprehensively to revenue cycle and…
- 4.The MHRA's combination of first-mover approvals (oral GLP-1 orforglipron first in Europe [10]), operational AI sandbox, simultaneous MHRA-NICE approval model, and new frameworks for microbiome medicines and digital mental health collectively make the UK the most structurally accessible major regulatory market for novel therapeutic and digital health developers. Companies with products in these categories should model the UK as a first-launch market.
- 5.The MDUFA VI congressional submission deadline of January 15, 2027 and enactment deadline of September 30, 2027 [17] — combined with the new FDA Commissioner nomination — create a defined and time-sensitive window for medtech industry stakeholders to engage Congress on user fee structures and AI-enabled device review commitments that will govern approvals for the next authorization cycle.
- 6.The AMA's Ethical AI Use in Medicine CME Series [20] will create a physician-level AI evaluation standard that could directly influence hospital procurement decisions. AI health technology vendors should proactively align their product documentation and clinical evidence to the AMA's ethical framework to reduce adoption friction as this standard propagates through hospital credentialing and oversight processes.
- 7.Employer healthcare cost projections converging at 9–9.5% for 2027, combined with California's move toward enforcement penalties for providers exceeding spending targets, signals that cost containment is becoming coercive rather than aspirational [6]. Value-based care companies and AI administrative efficiency tools — particularly those targeting prior authorization, revenue cycle, and care management — are structurally positioned to benefit from this shift.
- 8.Japan's coordinated institutional build — MHLW Healthcare AX/DX Promotion Headquarters, PMDA ENSEMBLExJ One-Stop Service Platform, and the 6th SaMD Industry-Academia-Government Collaboration Forum [16] — represents a systematic reduction of market entry barriers that companies with SaMD and digital health products should treat as a near-term market opportunity rather than a long-term aspiration.
- 9.The Merck-Moderna mRNA cancer vaccine pivotal success in melanoma [6] validates the personalized cancer vaccine platform at a scale that will accelerate investment and competitive entry across the broader mRNA oncology space. Companies developing competing personalized cancer immunotherapy approaches should anticipate compressed development timelines and accelerated capital competition.
- 10.The Cyclospora outbreak's growth to 10,930 cases despite a recall in place since July 17 — with FDA now expanding inspections beyond Taylor Farms to other Mexican growers [14] — demonstrates that recall execution and case identification lag significantly behind outbreak spread. Digital health companies with real-time foodborne illness surveillance and supply chain traceability capabilities have a concrete, high-profile case study to deploy in regulatory and health system conversations.
信頼度サマリー
今週引用したソース 25 件あなたが選んだ 30 件の監視URLから検出（1つのURLから複数記事が出ることがあります）。
各ソースは信頼度レベルに応じて重み付けされています。単独ソースの主張は AI 合成時に未検証としてフラグ付けされます。
参照ソース一覧
FDA news events covering first-in-class approvals including robotic blood draw device, gene therapy for glycogen storage disease, and August final-week approval cluster
FDA press announcements covering freeze-dried plasma approval, narcolepsy drug, melanoma immunotherapy, generative AI medical device public comment, and TEMPO digital health pilot
FDA recalls and safety alerts tracking drug contamination recalls and device safety issues across the month
PMDA English-language publications including review reports for Optune Lua, Esprit BTK scaffold, Avarept, regenerative medicine product list, companion diagnostic approval, and ENSEMBLExJ platform
Fierce Healthcare reporting on Epic FTC antitrust investigation, AI governance gap study, employer cost projections, and digital health M&A activity
MedCity News reporting on Function Health raise, digital health M&A, Replimune Tudriqev approval, BMS Zenbexus, ransomware breach, Merck-Moderna mRNA vaccine, and August first-in-class approvals
Kaiser Health News reporting on rural AI healthcare patient wariness and California healthcare spending enforcement
NIH news covering AI language pattern depression prediction research and cancer model cataloguing
CDC newsroom covering Cyclospora outbreak updates, Salmonella alfalfa sprout outbreak warning, and kindergarten vaccination rate data
UK MHRA covering AI sandbox launch, ambient voice technology guidance, aficamten simultaneous approval, orforglipron first-in-Europe authorization, microbiome medicines framework, digital mental health guidance, and Innovation Passport grants
Siemens Healthineers press releases covering Cleveland Clinic 10-year alliance, Vanderbilt Value Partnership, and ARPA-H remote endovascular robotics funding
NICE UK news covering aficamten simultaneous recommendation, lung preservation machine conditional recommendation, once-weekly insulin recommendation, and acalabrutinib recommendations
Epic Systems newsroom covering diagnostic image exchange, Chart with Art AI nursing documentation, real-time prior authorization checks, and Ergo Visit outpatient tool
FDA Cyclospora outbreak investigation tracking escalation from initial cases through 10,930 illnesses and expanded Mexico inspections
FDA warning letters targeting CGMP violations across multiple international pharmaceutical manufacturers
Japan MHLW announcements covering Healthcare AX/DX Promotion Headquarters establishment, SaMD Industry-Academia-Government Collaboration Forum, and advisory committee sessions
AdvaMed MDUFA VI statement expressing strong support for draft agreement and outlining January 2027 congressional submission and September 2027 enactment timeline
Philips news covering ARPA-H AI robotic stroke care program selection and COMBINE-CT clinical validation advancement
Cochrane news covering coordinated global public health organization childhood vaccination safety statement
AMA press releases covering childhood vaccination schedule warning, Ethical AI Use in Medicine CME Series launch, and prior authorization CMS response
Stryker news covering Mako RPS full market release and network disruption disclosure
BD news covering PREVENT trial enrollment completion, STANCE trial milestone, and Chief Quality Officer appointment
UnitedHealth Group newsroom covering behavioral coaching expansion to 13 million commercial members
Boston Scientific news covering cyberattack disclosure disrupting global IT systems and order shipping
AdvaMed statement welcoming Dr. Heidi Overton FDA Commissioner nomination and emphasizing CDRH transparency priorities
Healthcare AI & Digital Healthを毎週、自動で監視
このレポートは一次ソースのみから生成されています。テーマとソースを選べば、引用付きレポートが毎週届きます。7日間無料トライアル・$33/月から。
無料トライアルを始める